The GPCR-Targeted Drug Discovery Summit is the industry's leading meeting dedicated to advancing GPCR drug discovery and next-generation GPCR therapeutics. Now in its 6th year, the summit brings together scientists from pharma, biotech and academia who are discovering novel GPCR targets, applying AI-enabled drug discovery approaches, and translating receptor biology into therapeutic opportunities.
The meeting focuses on the scientific and technical challenges shaping the future of GPCR drug discovery, from orphan GPCRs and signaling biology to structural biology, screening technologies and emerging therapeutic modalities.
The 6th GPCR-Targeted Drug Discovery Summit is the industry's dedicated meeting for scientists advancing next-generation GPCR therapeutics. Whether you're working on novel GPCR targets, orphan GPCRs, AI-enabled drug discovery, GPCR signaling biology or emerging therapeutic modalities, the summit provides a focused forum to benchmark approaches, share data and connect with peers tackling similar scientific challenges.
The program spans the most pressing areas of GPCR drug discovery, including:
- Beyond GLP-1 therapeutic opportunities
- Novel and emerging GPCR targets
- Orphan GPCRs and deorphanization strategies
- Dark and super-dark GPCR biology
- GPCR target validation
- AI for GPCR drug discovery
- Structure-guided drug design
- Cryo-EM and GPCR structural biology
- GPCR signaling and biased agonism
- Functional selectivity and receptor activation
- DNA-encoded library screening
- GPCR antibodies and biologics
- Multi-receptor therapeutics and polypharmacology
The success of GLP-1 receptor agonists has intensified interest in identifying the next generation of GPCR therapeutics.
Researchers are increasingly focused on discovering novel GPCR targets, understanding underexplored receptor biology, and applying new technologies to unlock opportunities across obesity, metabolic disease, immunology, CNS disorders and oncology. The summit is designed to help teams identify where the next major breakthroughs may emerge.
Yes. Orphan GPCR drug discovery is a major theme throughout the meeting.
Sessions explore deorphanization strategies, target validation, receptor biology and approaches for progressing dark GPCRs and underexplored receptors into viable therapeutic opportunities. Attendees will hear how leading teams are assessing biological relevance, disease linkage and translational potential within previously uncharacterized receptor families.
AI-enabled drug discovery is a dedicated focus area of the summit.
Attendees will learn how organizations are applying machine learning, computational pharmacology, virtual screening and structure-based approaches to accelerate target identification, ligand discovery and candidate optimization for GPCR programs.
Yes. Advances in GPCR structural biology continue to transform receptor-targeted drug discovery.
The summit includes presentations covering cryo-EM, structure-guided drug design, receptor conformational analysis and other approaches that are improving our understanding of receptor activation and enabling more rational therapeutic design.
A major focus of the meeting is understanding receptor activation, signaling pathways and functional outcomes beyond simple binding interactions.
Attendees will hear case studies covering GPCR signaling, biased agonism, functional selectivity, compartmentalized signaling, biosensors and translational pharmacology approaches designed to better predict therapeutic outcomes.
The program highlights a range of emerging technologies supporting modern GPCR drug discovery, including:
- AI-enabled drug discovery platforms
- Machine learning approaches
- Structure-based drug design
- Cryo-EM
- DNA-encoded library (DEL) screening
- Virtual screening
- Advanced GPCR screening technologies
- Translational pharmacology tools
- GPCR biosensors
Yes. The summit examines how developers are expanding beyond traditional small-molecule approaches through:
- GPCR antibodies
- Agonist antibodies
- GPCR biologics
- Peptide therapeutics
- Multi-receptor therapeutics
- Precision pharmacology strategies
- Novel therapeutic modalities
The goal is to understand which emerging approaches are generating the strongest scientific and translational momentum.
Absolutely.
While the success of GLP-1 therapies remains a major industry focus, the meeting explores GPCR opportunities across multiple therapeutic areas, including:
- Obesity and metabolic disease
- Immunology
- Autoimmune disease
- CNS disorders
- Neurobiology
- Oncology
- Inflammatory disorders
- Rare diseases
This makes the summit valuable for organizations exploring GPCR biology beyond the current metabolic disease landscape.
Unlike broader pharmacology or drug discovery meetings, the 6th GPCR-Targeted Drug Discovery Summit is built specifically around the challenges facing discovery and translational teams developing next-generation GPCR therapeutics.
The agenda focuses on:
- Beyond GLP-1 opportunities
- Novel GPCR targets
- Orphan and dark GPCRs
- AI-driven GPCR discovery
- Signaling biology
- Structural biology
- Emerging therapeutic modalities
The format also ensures every attendee participates in the same scientific discussions, creating more meaningful networking and scientific exchange.
Yes.
The summit is intentionally designed as a highly interactive meeting where attendees can engage directly with peers working on similar scientific challenges.
Networking opportunities include:
- Speed networking sessions
- Interactive discussion periods
- Dedicated networking breaks
- Poster sessions
- Roundtable discussions
- Evening networking receptions
- Burning Questions sessions
With a focused audience of GPCR discovery specialists, attendees can build relationships that extend well beyond the event itself.
Explore the Agenda
Discover the latest advances in AI-enabled discovery, target validation, signaling biology, and emerging GPCR therapeutics across three days of scientific discussion.
Partner With Us
Showcase your expertise to a highly targeted audience of scientists and decision-makers actively seeking technologies, services, and partners to accelerate GPCR discovery.
Join the GPCR Community
Connect with leading pharma, biotech, and academic experts tackling the biggest challenges and opportunities shaping the future of GPCR drug discovery.